Royalty Pharma will report its 2025 financial results on February 11, 2026, with a conference call at 8:00 a.m. ET.
Quiver AI Summary
Royalty Pharma plc announced that it will release its fourth quarter and full year 2025 financial results on February 11, 2026, before the U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on that date. Interested parties can find details on the company's website and access a replay of the call for 30 days. Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties, financing innovation through partnerships with various sectors of the biopharmaceutical industry, and holds royalties for over 35 commercial products and 20 development-stage candidates. For more information, visit their website.
Potential Positives
- Royalty Pharma is set to report its fourth quarter and full year 2025 financial results, indicating transparency and commitment to providing timely updates to investors.
- The company will host a conference call and webcast, allowing for direct engagement with investors and analysts, enhancing shareholder communication.
- Royalty Pharma's strong portfolio includes royalties on over 35 commercial products, highlighting its significant market position and diverse revenue streams.
Potential Negatives
- Potential concerns about upcoming financial results may indicate previous operational or market challenges, particularly if investors anticipate disappointing performance based on trends or prior announcements.
- The timing of the announcement prior to the financial results may indicate a lack of confidence, as it requires heightened focus from investors on the quarterly performance.
- The phrasing around their portfolio suggests reliance on a limited number of high-profile products, which may pose risks if any of those products underperform or face market challenges.
FAQ
When will Royalty Pharma report its financial results for 2025?
Royalty Pharma will report its financial results on Wednesday, February 11, 2026, before U.S. markets open.
What time is the Royalty Pharma conference call?
The conference call will take place at 8:00 a.m. Eastern Time on February 11, 2026.
How can I access the Royalty Pharma conference call webcast?
You can access the webcast by visiting the “Investors” page on Royalty Pharma's website.
Will the conference call be available for replay?
Yes, a replay of the conference call and webcast will be archived on the company's website for at least 30 days.
What does Royalty Pharma do?
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of biopharmaceutical innovation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- GEORGE W. LLOYD (EVP, Investments & CLO) has made 0 purchases and 11 sales selling 355,426 shares for an estimated $13,807,997.
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 12 sales selling 347,922 shares for an estimated $13,534,004.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 8 sales selling 163,151 shares for an estimated $6,423,319.
- GREGORY NORDEN sold 33,500 shares for an estimated $1,213,748
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPRX Revenue
$RPRX had revenues of $609.3M in Q3 2025. This is an increase of 7.9% from the same period in the prior year.
You can track RPRX financials on Quiver Quantitative's RPRX stock page.
$RPRX Hedge Fund Activity
We have seen 295 institutional investors add shares of $RPRX stock to their portfolio, and 187 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 25,441,140 shares (-69.9%) from their portfolio in Q3 2025, for an estimated $897,563,419
- FMR LLC removed 12,371,107 shares (-30.7%) from their portfolio in Q3 2025, for an estimated $436,452,654
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,965,633 shares (+99.4%) to their portfolio in Q3 2025, for an estimated $210,467,532
- CAPITAL INTERNATIONAL INVESTORS added 5,332,074 shares (+24.4%) to their portfolio in Q3 2025, for an estimated $188,115,570
- VIKING GLOBAL INVESTORS LP removed 2,597,460 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $91,638,388
- JUPITER ASSET MANAGEMENT LTD removed 2,470,706 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $87,166,507
- MORGAN STANLEY removed 2,440,149 shares (-5.2%) from their portfolio in Q3 2025, for an estimated $86,088,456
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- Goldman Sachs issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 3 analysts offer price targets for $RPRX in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Steve Scala from TD Cowen set a target price of $45.0 on 12/11/2025
- Terence Flynn from Morgan Stanley set a target price of $54.0 on 10/10/2025
- Asad Haider from Goldman Sachs set a target price of $42.0 on 09/30/2025
Full Release
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
[email protected]
